{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:43:51Z","timestamp":1793396631420,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajo.2026.04.021","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:25:38Z","timestamp":1776813938000},"page":"131-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy"],"prefix":"10.1016","volume":"288","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-5218","authenticated-orcid":false,"given":"Jui","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-5300","authenticated-orcid":false,"given":"Bhargav","family":"Makwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7219-7497","authenticated-orcid":false,"given":"Krisha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6006-2970","authenticated-orcid":false,"given":"Vahin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-0794","authenticated-orcid":false,"given":"Tirth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Khadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUJA","family":"Vivekanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagriti","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Moynihan","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-812X","authenticated-orcid":false,"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajo.2026.04.021_bib0001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ajo.2026.04.021_bib0002","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.021_bib0003","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.021_bib0004","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.021_bib0005","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.021_bib0006","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ajo.2026.04.021_bib0007","article-title":"GLP-1 receptor agonist in non-obese patients with type-2 diabetes mellitus and heart failure with preserved ejection fraction","author":"Khadke","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.ajo.2026.04.021_bib0008","article-title":"Obesity and cardiovascular-kidney-metabolic health: ethnicity-based risk and clinical considerations","author":"Ghanta","year":"2024","journal-title":"Cardiol Clin"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.021_bib0009","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.13550","article-title":"Association between diabetic eye disease and other complications of diabetes: implications for care. a systematic review","volume":"21","author":"Pearce","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.021_bib0010","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.ophtha.2020.12.019","article-title":"Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality","volume":"128","author":"Modjtahedi","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100734","article-title":"Risk of retinal vein occlusion between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a retrospective cohort study","volume":"7","author":"Pan","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.021_bib0012","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Open"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.021_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.13492","article-title":"Cardiovascular protection in type 2 diabetes: insights from recent outcome trials","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajo.2026.04.021_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta- analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"10278","key":"10.1016\/j.ajo.2026.04.021_bib0015","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2026.04.021_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an Aggregated Electronic Health Record Data Study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.021_bib0017","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMA Open"},{"key":"10.1016\/j.ajo.2026.04.021_bib0018","doi-asserted-by":"crossref","first-page":"m4856","DOI":"10.1136\/bmj.m4856","article-title":"STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.021_bib0019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajo.2026.04.021_bib0020","unstructured":"U.S. Centers for Disease Control and Prevention. Vision and eye Health surveillance system. VEHSS modeled estimates: prevalence of diabetic retinopathy. May 15, 2024. Accessed April 28, 2025. https:\/\/www.cdc.gov\/vision-health-data\/prevalence-estimates\/dr-prevalence.html."},{"issue":"5","key":"10.1016\/j.ajo.2026.04.021_bib0021","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.preteyeres.2007.06.001","article-title":"Neovascular glaucoma","volume":"26","author":"Hayreh","year":"2007","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.021_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201627","article-title":"Risk of retinal artery occlusion in patients with diabetes mellitus: a retrospective large-scale cohort Study","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2026.04.021_bib0023","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","article-title":"Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats","volume":"127","author":"Fan","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2026.04.021_bib0024","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.021_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.021_bib0026","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"9683","key":"10.1016\/j.ajo.2026.04.021_bib0027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ajo.2026.04.021_bib0028","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2026.04.021_bib0029","unstructured":"Novo Nordisk. Highlights of prescribing information. OZEMPIC (semaglutide) injection, for subcutaneous use. Initial U.S. Approval, December 2017. Accessed February 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"10.1016\/j.ajo.2026.04.021_bib0030","unstructured":"Eli Lilly and Company. Highlights of prescribing information. TRULICITY (dulaglutide) injection, for subcutaneous use. Initial U.S. Approval: 2014. Revised September 2018. Accessed February 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125469s023lbl.pdf"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.021_bib0031","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1755-5922.2011.00308.x","article-title":"Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Buehler","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"24","key":"10.1016\/j.ajo.2026.04.021_bib0032","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.021_bib0033","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1464-5491.2007.02327.x","article-title":"Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"25","author":"Targher","year":"2008","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.ajo.2026.04.021_bib0034","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2337\/dc11-0079","article-title":"Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies","volume":"34","author":"Kramer","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ajo.2026.04.021_bib0035","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2337\/dc12-1311","article-title":"Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial","volume":"36","author":"Gerstein","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.021_bib0036","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/dc07-0264","article-title":"Diabetic retinopathy and the risk of coronary heart disease: the atherosclerosis risk in communities study","volume":"30","author":"Cheung","year":"2007","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.021_bib0037","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac097","article-title":"Diabetic retinopathy may be a predictor of stroke in patients with diabetes mellitus","volume":"6","author":"Wang","year":"2022","journal-title":"J Endocr Soc"},{"issue":"12","key":"10.1016\/j.ajo.2026.04.021_bib0038","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1161\/STROKEAHA.120.030350","article-title":"Diabetic retinopathy and risk of stroke: a secondary analysis of the ACCORD eye study","volume":"51","author":"Wong","year":"2020","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.ajo.2026.04.021_bib0039","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajo.2026.04.021_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1007980","article-title":"Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.ajo.2026.04.021_bib0041","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4239\/wjd.v13.i12.1035","article-title":"Keeping an eye on the diabetic foot: the connection between diabetic eye disease and wound healing in the lower extremity","volume":"13","author":"Ramsey","year":"2022","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.021_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91954-1","article-title":"Quality of life, body image and self-esteem in patients with unilateral transtibial amputations","volume":"11","author":"Sarroca","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.021_bib0043","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.021_bib0044","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.ki.5000377","article-title":"Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective","volume":"69","author":"Parving","year":"2006","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ajo.2026.04.021_bib0045","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/dom.14776","article-title":"Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Yuan","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.021_bib0046","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.021_bib0047","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.021_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.ajo.2026.04.021_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.021_bib0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2026.04.021_bib0051","article-title":"Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2026.04.021_bib0052","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:34:34Z","timestamp":1783442074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["S0002939426002199"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.021","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}